| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| H Jones, V A Curtis, P A Wright, J V Luce. Risperidone is associated with blunting of D-fenfluramine evoked serotonergic responses in schizophrenia. International clinical psychopharmacology. vol 13. issue 5. 1999-01-29. PMID:9817624. |
risperidone is associated with blunting of d-fenfluramine evoked serotonergic responses in schizophrenia. |
1999-01-29 |
2023-08-12 |
Not clear |
| L C Kopala, C Day, B Dillman, D Gardne. A case of risperidone overdose in early schizophrenia: a review of potential complications. Journal of psychiatry & neuroscience : JPN. vol 23. issue 5. 1999-01-13. PMID:9846036. |
a case of risperidone overdose in early schizophrenia: a review of potential complications. |
1999-01-13 |
2023-08-12 |
Not clear |
| W J Naja, J P Reneric, M P Bouvar. [Atypical neuroleptics in the child and adolescent]. L'Encephale. vol 24. issue 4. 1999-01-05. PMID:9809243. |
since 1992 several studies concerning children and adolescents show the efficiency and the tolerance of the clozapine and risperidone in various disorders, especially in very early onset schizophrenia (veos). |
1999-01-05 |
2023-08-12 |
human |
| S A Chong, R Mahendran, K E Won. Use of atypical neuroleptics in a state mental institute. Annals of the Academy of Medicine, Singapore. vol 27. issue 4. 1998-12-30. PMID:9791664. |
both clozapine and risperidone are efficacious in reducing the psychotic symptomatology of schizophrenia as well as inducing less extrapyramidal side-effects. |
1998-12-30 |
2023-08-12 |
human |
| S A Chong, R Mahendran, K E Won. Use of atypical neuroleptics in a state mental institute. Annals of the Academy of Medicine, Singapore. vol 27. issue 4. 1998-12-30. PMID:9791664. |
both clozapine and risperidone are efficacious and safe in the treatment of schizophrenia. |
1998-12-30 |
2023-08-12 |
human |
| C M Yee, K H Nuechterlein, S E Morris, P M Whit. P50 suppression in recent-onset schizophrenia: clinical correlates and risperidone effects. Journal of abnormal psychology. vol 107. issue 4. 1998-12-18. PMID:9830258. |
p50 suppression in recent-onset schizophrenia: clinical correlates and risperidone effects. |
1998-12-18 |
2023-08-12 |
Not clear |
| B S Nightengale, J M Crumly, J Liao, B J Lawrence, E W Jacob. Economic outcomes of antipsychotic agents in a Medicaid population: traditional agents vs. risperidone. Psychopharmacology bulletin. vol 34. issue 3. 1998-12-09. PMID:9803771. |
this study assessed the differential impact of risperidone and traditional agents on the total schizophrenia-related cost of care for medicaid patients suffering from schizophrenia. |
1998-12-09 |
2023-08-12 |
Not clear |
| M Iskedjian, M Hux, G J Remingto. The Canadian experience with risperidone for the treatment of schizophrenia: an overview. Journal of psychiatry & neuroscience : JPN. vol 23. issue 4. 1998-11-30. PMID:9785702. |
the canadian experience with risperidone for the treatment of schizophrenia: an overview. |
1998-11-30 |
2023-08-12 |
Not clear |
| M Iskedjian, M Hux, G J Remingto. The Canadian experience with risperidone for the treatment of schizophrenia: an overview. Journal of psychiatry & neuroscience : JPN. vol 23. issue 4. 1998-11-30. PMID:9785702. |
to summarize published data to date by canadian authors and from canadian sources on risperidone, a novel neuroleptic indicated in the management of schizophrenia and related psychotic disorders. |
1998-11-30 |
2023-08-12 |
Not clear |
| K S Kee, R S Kern, B D Marshall, M F Gree. Risperidone versus haloperidol for perception of emotion in treatment-resistant schizophrenia: preliminary findings. Schizophrenia research. vol 31. issue 2-3. 1998-11-09. PMID:9689720. |
risperidone versus haloperidol for perception of emotion in treatment-resistant schizophrenia: preliminary findings. |
1998-11-09 |
2023-08-12 |
Not clear |
| K S Kee, R S Kern, B D Marshall, M F Gree. Risperidone versus haloperidol for perception of emotion in treatment-resistant schizophrenia: preliminary findings. Schizophrenia research. vol 31. issue 2-3. 1998-11-09. PMID:9689720. |
the present study was designed to compare the effects of risperidone versus haloperidol on the ability to perceive emotion in 20 treatment-resistant schizophrenia patients, using a double-blind design. |
1998-11-09 |
2023-08-12 |
Not clear |
| S Kasper, B Küfferl. Comments on "Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders" by Tran and Associates. Journal of clinical psychopharmacology. vol 18. issue 4. 1998-10-28. PMID:9690709. |
comments on "double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders" by tran and associates. |
1998-10-28 |
2023-08-12 |
Not clear |
| H J Möller, C A Gagiano, D E Addington, L Von Knorring, J F Torres-Plank, C Gaussare. Long-term treatment of chronic schizophrenia with risperidone: an open-label, multicenter study of 386 patients. International clinical psychopharmacology. vol 13. issue 3. 1998-10-28. PMID:9690975. |
long-term treatment of chronic schizophrenia with risperidone: an open-label, multicenter study of 386 patients. |
1998-10-28 |
2023-08-12 |
Not clear |
| H J Möller, C A Gagiano, D E Addington, L Von Knorring, J F Torres-Plank, C Gaussare. Long-term treatment of chronic schizophrenia with risperidone: an open-label, multicenter study of 386 patients. International clinical psychopharmacology. vol 13. issue 3. 1998-10-28. PMID:9690975. |
an open-label, multicentre study was conducted to assess the long-term efficacy and safety of risperidone in patients with chronic schizophrenia. |
1998-10-28 |
2023-08-12 |
Not clear |
| H J Möller, C A Gagiano, D E Addington, L Von Knorring, J F Torres-Plank, C Gaussare. Long-term treatment of chronic schizophrenia with risperidone: an open-label, multicenter study of 386 patients. International clinical psychopharmacology. vol 13. issue 3. 1998-10-28. PMID:9690975. |
the results demonstrate that risperidone's efficacy against the positive and negative symptoms of chronic schizophrenia can be maintained in long-term treatment with a low incidence of adverse experiences; moreover, the drug reduces preexisting extrapyramidal symptoms over time. |
1998-10-28 |
2023-08-12 |
Not clear |
| R S Shiwach, T J Carmod. Prolactogenic effects of risperidone in male patients--a preliminary study. Acta psychiatrica Scandinavica. vol 98. issue 1. 1998-10-28. PMID:9696519. |
this preliminary study describes a case of a male patient who developed gynaecomastia and sexual difficulties whilst taking risperidone for chronic paranoid schizophrenia. |
1998-10-28 |
2023-08-12 |
Not clear |
| S A Cohen, K Ihrig, R S Lott, J M Kerric. Risperidone for aggression and self-injurious behavior in adults with mental retardation. Journal of autism and developmental disorders. vol 28. issue 3. 1998-10-08. PMID:9656134. |
risperidone has proven efficacy with reduced likelihood of causing extrapyramidal symptoms in the treatment of schizophrenia. |
1998-10-08 |
2023-08-12 |
Not clear |
| R H Foster, K L Go. Risperidone. A pharmacoeconomic review of its use in schizophrenia. PharmacoEconomics. vol 14. issue 1. 1998-09-22. PMID:10182198. |
the use of risperidone in preference to conventional antipsychotics in patients with chronic schizophrenia has been supported by several modelled studies, including a cost-effectiveness analysis that compared risperidone and haloperidol in chronic schizophrenia and a cost-utility study that compared the drug with oral haloperidol, depot haloperidol decanoate and depot fluphenazine decanoate for 1 year's treatment of an initially hospitalised chronic schizophrenic patient with moderate symptoms. |
1998-09-22 |
2023-08-12 |
Not clear |
| R H Foster, K L Go. Risperidone. A pharmacoeconomic review of its use in schizophrenia. PharmacoEconomics. vol 14. issue 1. 1998-09-22. PMID:10182198. |
risperidone had favourable cost-benefit ratios relative to conventional antipsychotic treatment in a study that investigated a scenario in which all patients hospitalised with newly diagnosed schizophrenia received conventional antipsychotic therapy for 6 months, and then those who did not respond received a 6-month trial of risperidone or clozapine. |
1998-09-22 |
2023-08-12 |
Not clear |
| R H Foster, K L Go. Risperidone. A pharmacoeconomic review of its use in schizophrenia. PharmacoEconomics. vol 14. issue 1. 1998-09-22. PMID:10182198. |
the other compared risperidone, olanzapine and oral haloperidol for the treatment of schizophrenia. |
1998-09-22 |
2023-08-12 |
Not clear |